{"id":22854,"date":"2017-08-19T09:24:22","date_gmt":"2017-08-19T13:24:22","guid":{"rendered":"http:\/\/therapytoronto.ca\/news\/?p=22854"},"modified":"2017-08-16T23:51:22","modified_gmt":"2017-08-17T03:51:22","slug":"newly-discovered-biomarkers-may-lead-to-promising-diagnostic-tool-for-alzheimers","status":"publish","type":"post","link":"https:\/\/therapytoronto.ca\/news\/2017\/08\/newly-discovered-biomarkers-may-lead-to-promising-diagnostic-tool-for-alzheimers\/","title":{"rendered":"Newly discovered biomarkers may lead to promising diagnostic tool for Alzheimer&#8217;s"},"content":{"rendered":"<p>From the\u00a0Ohio State University press release:<\/p>\n<blockquote>\n<p id=\"first\" class=\"lead\"><img loading=\"lazy\" class=\"alignright size-full wp-image-15339\" src=\"http:\/\/therapytoronto.ca\/news\/wp-content\/uploads\/2013\/08\/schizophrenia-memory-loss-2.jpg\" alt=\"\" width=\"280\" height=\"275\" \/>Diagnosing Alzheimer&#8217;s disease and determining a patient&#8217;s prognosis is an inexact business, and that stands in the way of better personalized care and advances in treatment.<\/p>\n<div id=\"text\">\n<p>A new study from The Ohio State University has identified a <strong>potential new way of confirming the disease and predicting a patient&#8217;s outlook<\/strong>.<\/p>\n<p>First, the team of researchers discovered new physical biomarkers that could help pinpoint a diagnosis &#8212; changes to proteins found in the spinal fluid and blood of patients. In particular, as Alzheimer&#8217;s severity increased, the proteins were longer, more rigid and more clustered, said lead researcher Mingjun Zhang, a professor of biomedical engineering at Ohio State.<\/p>\n<p>After finding these new clues to the disease, the research team entered information about the biomarkers and several other factors &#8212; including scores from cognitive assessments of patients &#8212; into an algorithm designed to rate the severity of illness.<\/p>\n<p>The researchers found that the equation could identify disease stages and progression.<\/p>\n<p>&#8220;With a tool like this you may predict how fast this disease will go, and currently we can&#8217;t do that &#8212; we just know everyone is different,&#8221; Zhang said. &#8220;Looking at multiple indicators of the disease all at once increases the reliability of the diagnosis and prognosis.&#8221;<\/p>\n<p>The research appears in the journal\u00a0<em>Science Advances<\/em>.<\/p>\n<p>The information used in the study came from a database of medical information &#8212; and samples of spinal fluid and blood &#8212; from patients seen by study co-author Douglas Scharre, a professor of clinical neurology and psychiatry in the Neurological Institute at Ohio State&#8217;s Wexner Medical Center.<\/p>\n<p>The experimental tools aren&#8217;t ready for clinical use yet, but could lead to improvements in treatment in multiple ways, Scharre said.<\/p>\n<p>&#8220;It was fairly easy to see changes between normal aging and different stages of Alzheimer&#8217;s disease using these biomarkers, and to see significant changes,&#8221; he said.<\/p>\n<p>Currently available medications treat only symptoms of the disease and work best with an early diagnosis. <strong>Improved diagnostic tools could help doctors sort out more quickly which patients have Alzheimer&#8217;s disease and which are experiencing cognitive decline for other reasons<\/strong>, Scharre said.<\/p>\n<p>Early evidence from tests of experimental drugs designed to alter the disease indicate that they would work best in the early stages as well, he said.<\/p>\n<p>And, ideally, these biomarkers and algorithm &#8212; or something similar &#8212; could speed up discovery of new treatments to improve the outlook for those with later stages of Alzheimer&#8217;s disease. Having an easily observable biomarker that changes quickly over time would be a powerful tool for those trying to monitor the impact of their experimental treatments, Scharre said.<\/p>\n<p>&#8220;A biomarker that shows that in three months, or three weeks even, that this drug is not doing a darn thing or is slowing down the disease will help us to not waste time in finding better treatments,&#8221; he said.<\/p>\n<p>Zhang said doctors treating patients with Alzheimer&#8217;s disease already try to take a number of factors about a given patient to estimate disease stage and to predict how quickly the disease will move.<\/p>\n<p>&#8220;We&#8217;ve taken what they do and converted it to a computational model with different weights for different factors,&#8221; Zhang said. &#8220;We&#8217;re using engineering techniques to look at a human disease process, a dynamic process.&#8221;<\/p>\n<p>Looking for physical changes in proteins is a growing area of interest for those seeking disease biomarkers, said Jeff Kuret, a study co-author and professor of biological chemistry and pharmacology at Ohio State.<\/p>\n<p>&#8220;The goal is to have a sensitive test that could be applied at the early stages of Alzheimer&#8217;s disease and would not be too expensive,&#8221; Kuret said.<\/p>\n<p>The study authors said it&#8217;s too soon to estimate how much tools such as this would cost if they were developed for routine use, but said that identifying a blood test &#8212; rather than one that relies on spinal fluid &#8212; would be key to minimizing risks and costs.<\/p>\n<p>Kuret said this kind of test is especially promising for Alzheimer&#8217;s because it&#8217;s a relatively slow-moving illness and one in which the ability to determine stages of disease could lead to better, more personalized treatments down the road.<\/p>\n<p>&#8220;To be able to follow individual patients from pre-symptomatic through all stages of Alzheimer&#8217;s progression would be incredibly helpful,&#8221; he said.<\/p>\n<\/div>\n<\/blockquote>\n<!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content -->","protected":false},"excerpt":{"rendered":"<p>From the\u00a0Ohio State University press release: Diagnosing Alzheimer&#8217;s disease and determining a patient&#8217;s prognosis is an inexact business, and that stands in the way of better personalized care and advances&#8230; <a class=\"read-more-link\" href=\"https:\/\/therapytoronto.ca\/news\/2017\/08\/newly-discovered-biomarkers-may-lead-to-promising-diagnostic-tool-for-alzheimers\/\">Read more &raquo;<\/a><!-- AddThis Advanced Settings generic via filter on get_the_excerpt --><!-- AddThis Share Buttons generic via filter on get_the_excerpt --><\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[321,10],"tags":[195,194,180,49],"_links":{"self":[{"href":"https:\/\/therapytoronto.ca\/news\/wp-json\/wp\/v2\/posts\/22854"}],"collection":[{"href":"https:\/\/therapytoronto.ca\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/therapytoronto.ca\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/therapytoronto.ca\/news\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/therapytoronto.ca\/news\/wp-json\/wp\/v2\/comments?post=22854"}],"version-history":[{"count":2,"href":"https:\/\/therapytoronto.ca\/news\/wp-json\/wp\/v2\/posts\/22854\/revisions"}],"predecessor-version":[{"id":22968,"href":"https:\/\/therapytoronto.ca\/news\/wp-json\/wp\/v2\/posts\/22854\/revisions\/22968"}],"wp:attachment":[{"href":"https:\/\/therapytoronto.ca\/news\/wp-json\/wp\/v2\/media?parent=22854"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/therapytoronto.ca\/news\/wp-json\/wp\/v2\/categories?post=22854"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/therapytoronto.ca\/news\/wp-json\/wp\/v2\/tags?post=22854"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}